Nicotine potentiates sulpiride-induced catalepsy in mice. 1998

M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences and Soha Research and Development Center, KM Tehran-Ghazvin HWY, Iran.

The effects of nicotine on sulpiride-induced catalepsy in mice were investigated. Sulpiride (12.5-100 mg/kg) induced a low degree of catalepsy in mice which was dose dependent. Nicotine (0.0001-1 mg/kg) caused an even lower degree of catalepsy. When the drugs were co-administered a much higher cataleptogenic response was obtained. The potentiation of the effect of sulpiride by nicotine was elicited by 0.5 mg/kg or higher doses of the drug. The central nicotinic receptor antagonist mecamylamine (1-3 mg/kg) and the peripheral antagonist hexamethonium (5 and 10 mg/kg) decreased the response induced by the combination of nicotine and sulpiride. Higher doses of the cholinoceptor antagonist atropine (10 mg/kg) also reduced the catalepsy induced by the drug combination. It is concluded that nicotine potentiates sulpiride-induced catalepsy through activation of cholinergic mechanism(s) and that the central nicotinic mechanism mediates nicotine's action.

UI MeSH Term Description Entries
D008297 Male Males
D008464 Mecamylamine A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D002375 Catalepsy A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions. Cerea Flexibilitas,Flexibility, Waxy,Anochlesia,Anochlesias,Catalepsies,Flexibilitas, Cerea,Flexibilities, Waxy,Waxy Flexibilities,Waxy Flexibility
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D013469 Sulpiride A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed) Aiglonyl,Arminol,Deponerton,Desisulpid,Digton,Dogmatil,Dolmatil,Eglonyl,Ekilid,Guastil,Lebopride,Meresa,Pontiride,Psicocen,Sulp,Sulperide,Sulpitil,Sulpivert,Sulpor,Synédil,Tepavil,Vertigo-Meresa,neogama,vertigo-neogama,Vertigo Meresa,vertigo neogama
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
April 1991, Pharmacology, biochemistry, and behavior,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
November 1981, Life sciences,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
October 1981, Journal of comparative and physiological psychology,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
January 2009, Natural product research,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
December 2012, Pharmacology, biochemistry, and behavior,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
October 1993, Pharmacology, biochemistry, and behavior,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
January 2009, Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
May 1997, European journal of pharmacology,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
August 1987, Methods and findings in experimental and clinical pharmacology,
M R Zarrindast, and F Haeri-Zadeh, and A Zarghi, and P Lahiji
September 1989, The International journal of neuroscience,
Copied contents to your clipboard!